This brief guide describes key aspects of the epidemiology, classification, and clinical presentation of myelofibrosis, as well as advances in molecular characterization and pathogenesis, clinical assessment and diagnosis, and therapy, in addition to the management of blast-phase myelofibrosis, the role of allo-stem cell transplantation, and the most promising agents in clinical trials. Annotation ©2022 Ringgold, Inc., Portland, OR (protoview.com)
Myelofibrosis is a myeloproliferative neoplasm that has markedly heterogeneous features. The clinical phenotype can range from initial indolent presentation, which may be stable for many years, through to marked cytopenias, debilitating constitutional symptoms, massive splenomegaly and an inherent risk of leukemic transformation. Despite many advances regarding molecular classification, prognostication models and rapeutic options over the last few decades, allogeneic stem cell transplantation remains the only curative option, yet is suitable only for a minority of patients. Fast Facts: Myelofibrosis is written for health professionals by two leading experts in the field, and provides up-to-date guidance on its accurate diagnosis, risk stratification and management. It also provides key insights into the molecular biology underpinning the disease. This concise handbook is an indispensable read for anyone wanting to get up to speed with best practice in the diagnosis and care of people with myelofibrosis. Table of Contents: Presentation, classification and epidemiology Molecular biology and pathogenesis Clinical assessment and diagnosis Prognostic models Treatment approaches Allogeneic stem cell transplantation Management of blast-phase myelofibrosis Therapies in development
